ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Endometrial Cancer
Ovarian Epithelial Carcinoma
Breast Cancer
Cancer
Fallopian Tube Cancer
Non-Small-Cell Lung Carcinoma
Triple Negative Breast Cancer

Ovarian Cancer trials near Madrid, MD, ESP:

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) (DO-01)

in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian...

Enrolling
Ovarian Cancer
Drug: Trastuzumab Deruxtecan
Drug: Bevacizumab

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 207 other locations

tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian...

Enrolling
Platinum-resistant Ovarian Cancer
Drug: MEN2501

Phase 1

Stemline Therapeutics
Stemline Therapeutics

Madrid, Spain and 14 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 126 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 213 other locations

A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate d...

Enrolling
Ovarian Cancer
Biological: THEO-260

Phase 1, Phase 2

Theolytics Limited

Madrid, Spain and 3 other locations

in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...

Active, not recruiting
Ovarian Cancer
Drug: carboplatin
Drug: paclitaxel

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 52 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Madrid, Spain and 46 other locations

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpos ...

Enrolling
Ovarian Cancer
Drug: Bevacizumab
Drug: Mirvetuximab Soravtansine

Phase 2

AbbVie
AbbVie

Madrid, Spain and 76 other locations

choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein ...

Enrolling
Ovarian Cancer
Drug: Azenosertib
Drug: Investigator's choice of Chemotherapy

Phase 3

K-Group Beta

Madrid, Spain and 57 other locations

positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

Phase 2

AbbVie
AbbVie

Madrid, Spain and 70 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems